Many people with obesity have undiagnosed sleep apnea, so a sleep study could open a door to coverage you did not know existed
Technology trajectory: The field is converging on three next-generation directions: (1) oral small molecule GLP-1RAs (Lilly, Pfizer, Roche, Viking all in Phase 3), (2) multi-receptor co-agonists with superior efficacy (retatrutide, survodutide, GLP-1/FGF21 combos), and (3) biased agonism for improved tolerability (Sciwinds ecnoglutide as proof of concept)
It also offers less side effects & more weight loss than first generation and GLP-1 medications only
DPP-4 inhibitors are commonly used alongside metformin or SGLT-2 inhibitors for additive blood glucose lowering
Perlman said
Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes